Cholinesterase inhibitors for dementia with Lewy bodies (Q24248036)

dementia with Lewy bodies

Europe PubMed Central

title

Cholinesterase inhibitors for dementia with Lewy bodies (English)

0 references

main subject

dementia

0 references

1 reference

Rebecca Wild

1

0 references

Tor ACL Pettit

series ordinal

2

0 references

Alistair Burns

series ordinal

3

0 references

publication date

21 July 2003

0 references

published in

Cochrane Database of Systematic Reviews

0 references

cites work

Dementia with lewy bodies: findings from an international multicentre study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

Donepezil for dementia due to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

Bias in treatment assignment in controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

A review of some statistical methods for covariance analysis of categorical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

Alzheimer's disease and Lewy body disease: a comparative clinicopathological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

The medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

Galantamine for Alzheimer's disease and mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

Cortical changes in the parkinsonian brain: a contribution to the delineation of "diffuse Lewy body disease".

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

Idiopathic clouding of consciousness?do the patients have cortical lewy body disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease?

21 January 2018

1 reference

12 December 2020

Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density.

1 reference

12 December 2020

Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease.

1 reference

12 December 2020

Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients

1 reference

12 December 2020

Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample

1 reference

12 December 2020

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

12 December 2020

What is the clinical prevalence of lewy body dementia?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

7 January 2021

inferred from DOI database lookup

Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003672

7 January 2021